Clinical Trials Logo

Clinical Trial Summary

This is a Prospective, Single-center, Single-arm, phase II clinical trial to explore the efficacy and safety of sintilimab (PD1 inhibitor) combined with XELOX chemotherapy, evaluate the pathological complete response rate of short-course radiotherapy combined with sintilimab and XELOX chemotherapy in neoadjuvant therapy for locally advanced gastric adenocarcinoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05563012
Study type Interventional
Source Renmin Hospital of Wuhan University
Contact Xiangpan Li, M.D.
Phone +86-027-88041911
Email rm001227@whu.edu.cn
Status Recruiting
Phase Phase 2
Start date September 26, 2022
Completion date October 1, 2026